Eloxx Pharmaceuticals (ELOX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-1 for Q2 FY2026, filed Sep 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ELOX SEC filings page.
Eloxx Pharmaceuticals, Inc. (ELOX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported business remains development-led: FY2024 revenue did not cover operating spending, while FY2025 cash inflow came mainly from financing.
In FY2025, operating cash flow of-$6.3M nearly matched a net loss of$6.0M , so losses were translating into cash needs rather than mostly accounting charges. Financing cash flow of$11.0M exceeded that operating use, making external funding the cash bridge.
The latest balance sheet is structurally strained: liabilities were
FY2024's development-stage spending pattern saw R&D and SG&A consume
Financial Health Signals
Eloxx Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Eloxx Pharmaceuticals, Inc. scores -84.71, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $300.6M against total assets of $5.3M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Eloxx Pharmaceuticals, Inc. passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.
Eloxx Pharmaceuticals, Inc. reported a net loss of $6.0M while operations used $6.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Eloxx Pharmaceuticals, Inc. reported a net loss of $4.5M in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Eloxx Pharmaceuticals, Inc. held $62.0M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Eloxx Pharmaceuticals, Inc.'s quarterly ROE was -9.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Eloxx Pharmaceuticals, Inc. invested $2.8M in research and development in Q2 2026. Against the prior quarter it is up 71.2%.
Not reported for Q2 2026.
Not reported for Q2 2026.
ELOX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q1'26S-1 | Q4'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q2'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $2.8M | $1.7M | N/A | $898K | $510K-59.2% | N/A | N/A | $1.3M-74.4% |
| SG&A Expenses | $1.6M | $2.1M | N/A | $684K | $712K-70.2% | N/A | N/A | $2.4M+5.5% |
| Operating Income | -$4.5M | -$3.8M | N/A | -$1.6M | -$1.2Mn/m | N/A | N/A | -$3.6Mn/m |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$3.6Mn/m |
| Interest Expense | $100K | $100K | N/A | $300K | $500K | N/A | N/A | N/A |
| Net Income | -$4.5M | -$3.8M | N/A | -$1.9M | -$1.7Mn/m | N/A | N/A | -$3.6Mn/m |
| EPS (Basic) | -$0.66 | -$0.86 | N/A | -$5.45 | -$4.94 | N/A | N/A | -$1.31 |
| EPS (Diluted) | -$0.66 | -$0.86 | N/A | -$5.45 | -$4.94 | N/A | N/A | -$1.31 |
| Diluted Shares (Avg) | 7M | 4M | N/A | 347,000 | 345,958 | N/A | N/A | 3M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
ELOX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q1'26S-1 | Q4'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q2'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $63.4M+2030.0% | $8.5M | $5.3M | N/A | N/A | $3.0M+73.8% | $1.7M-71.4% | $6.0M-77.5% |
| Current Assets | $63.4M+2030.0% | $8.5M | $5.3M | N/A | N/A | $3.0M+92.2% | $1.5M-71.2% | $5.6M-78.1% |
| Cash & Equivalents | $62.0M+55719.8% | $6.4M | $4.8M+736.5% | $572K | $450K-90.6% | $111K-90.2% | $1.1M-73.8% | $4.8M-80.6% |
| Short-Term Investments | $0n/m | $0 | $0n/m | $0 | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0 | $0n/m | $0 | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $17.0M-37.9% | $16.1M | $17.2M | N/A | N/A | $27.3M+12.3% | $24.3M-1.1% | $26.1M-18.1% |
| Current Liabilities | $17.0M-37.9% | $16.1M | $17.2M | N/A | N/A | $27.3M+20.3% | $22.7M+6.8% | $23.5M+8.2% |
| Non-Current Liabilities | $0n/m | $0 | $0 | N/A | N/A | $0-100.0% | $1.6M-51.6% | $2.6M-74.2% |
| Long-Term Debt | N/A | N/A | $0 | N/A | N/A | $0-100.0% | $1.6M-51.6% | $2.6M-73.4% |
| Total Equity | $46.4Mn/m | -$7.6M | -$11.9Mn/m | -$27.9M | -$26.0Mn/m | -$24.3Mn/m | -$22.6Mn/m | -$20.0Mn/m |
| Retained Earnings | -$308.8Mn/m | -$304.3M | -$300.6M | N/A | N/A | -$294.6Mn/m | -$291.4Mn/m | -$288.6Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ELOX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'26S-1 | Q1'26S-1 | Q4'26S-1 | Q4'25S-1 | Q3'25S-1 | Q2'25S-1 | Q2'24S-1 | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.8M | -$5.5M | N/A | -$1.8M | $1.2Mn/m | N/A | -$2.0Mn/m | -$3.5Mn/m |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | $73K+508.3% | $13K-43.5% |
| Stock-Based Compensation | $95K | $46K | N/A | $16K | $20K-95.2% | N/A | N/A | $418K-41.5% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$3.5Mn/m |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $51K+264.3% | $233Kn/m |
| Financing Cash Flow | $60.4M | $7.0M | N/A | $1.9M | -$865K-123.6% | N/A | -$1.7M-217.6% | $3.7M+144.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ELOX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$11.9M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.31), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Where Eloxx Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
What is Eloxx Pharmaceuticals, Inc.'s annual revenue?
Eloxx Pharmaceuticals, Inc. (ELOX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Eloxx Pharmaceuticals, Inc.'s revenue growing?
Eloxx Pharmaceuticals, Inc. (ELOX) revenue declined by 100.0% year-over-year, from $6.4M to $0 in fiscal year 2025.
Is Eloxx Pharmaceuticals, Inc. profitable?
No, Eloxx Pharmaceuticals, Inc. (ELOX) reported a net loss of $6.0M in fiscal year 2025.
What is Eloxx Pharmaceuticals, Inc.'s EBITDA?
Eloxx Pharmaceuticals, Inc. (ELOX) had EBITDA of -$6.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Eloxx Pharmaceuticals, Inc. have?
As of fiscal year 2025, Eloxx Pharmaceuticals, Inc. (ELOX) had $4.8M in cash and equivalents against $0 in long-term debt.
What is Eloxx Pharmaceuticals, Inc.'s operating cash flow?
Eloxx Pharmaceuticals, Inc. (ELOX) recorded an outflow of $6.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Eloxx Pharmaceuticals, Inc.'s total assets?
Eloxx Pharmaceuticals, Inc. (ELOX) had $5.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Eloxx Pharmaceuticals, Inc. spend on research and development?
Eloxx Pharmaceuticals, Inc. (ELOX) invested $3.1M in research and development during fiscal year 2025.
What is Eloxx Pharmaceuticals, Inc.'s current ratio?
Eloxx Pharmaceuticals, Inc. (ELOX) had a current ratio of 0.31 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Eloxx Pharmaceuticals, Inc.'s return on assets (ROA)?
Eloxx Pharmaceuticals, Inc. (ELOX) had a return on assets of -113.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Eloxx Pharmaceuticals, Inc.'s P/E ratio?
Eloxx Pharmaceuticals, Inc. (ELOX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $53.8M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Eloxx Pharmaceuticals, Inc.'s price-to-sales ratio?
Eloxx Pharmaceuticals, Inc. (ELOX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $53.8M as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Eloxx Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Eloxx Pharmaceuticals, Inc. (ELOX) held $4.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.3M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Eloxx Pharmaceuticals, Inc.'s debt-to-equity ratio negative or not reported?
Eloxx Pharmaceuticals, Inc. (ELOX) has negative shareholder equity of -$11.9M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Eloxx Pharmaceuticals, Inc.'s Altman Z-Score?
Eloxx Pharmaceuticals, Inc. (ELOX) has an Altman Z-Score of -84.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Eloxx Pharmaceuticals, Inc.'s Piotroski F-Score?
Eloxx Pharmaceuticals, Inc. (ELOX) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Eloxx Pharmaceuticals, Inc.'s earnings high quality?
Eloxx Pharmaceuticals, Inc. (ELOX) reported a net loss of $6.0M while operations used $6.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.